团队一直致力于炎症与肿瘤的发生机制及脂氧素功能研究，研究重点为肿瘤免疫微环境，已培养硕士研究生7名，在读研究生3名，在读的2023级硕士生已发表一作/共一SCI论文7篇（最高IF15.7）。导师所在杨浦医院病理科为杨浦区区域性病理诊断中心，院重点学科。导师为Advanced Science、Cancer Letters、International Journal of Biological Science、Journal of Translational Medicine、Journal of Leukocyte Biology、International Immunopharmacology、Therapeutic Advances in Medical Oncology、Cellular Signalling、Cancer Medicine、Experimental Cell Research、European Journal of Medical Research、Journal of Cosmetic Dermatology、Acta Histochemica、Renal Failure等杂志审稿专家，主持国家自然科学基金1项，省部级课题5项，市厅级课题4项，区级课题1项，院级课题4项。发表一作（含共一）及通讯作者SCI论文28篇（最高IF15.7）。

Advanced Science、Cancer Letters、International Journal of Biological Sciences、Journal of Translational Medicine、Journal of Leukocyte Biology、International Immunopharmacology、Therapeutic Advances in Medical Oncology、Cellular Signalling、Cancer Medicine、Experimental Cell Research、European Journal of Medical Research、Journal of Cosmetic Dermatology、Acta Histochemica、Renal Failure等杂志审稿专家，主持国家自然科学基金1项，省部级课题5项，市厅级课题4项，区级课题1项，院级课题4项。发表一作（含共一）及通讯作者SCI论文28篇（最高IF15.7）。

目前在研课题：

1.《穿刺洗脱液用于乳腺癌淋巴结或转移灶良恶性判断的研究方案》 2022-2024 上海市卫健委课题 No.202140232，20万。

2.《脂氧素 A4 调控肿瘤相关成纤维细胞 TGFβ-Smad2/3 通路抑制肝癌的机制研究》2021-2022 同济大学附属杨浦医院引进人才科研启动项目，10万。

3. 2022-2024同济大学附属杨浦医院第十批攀登计划项目，No. Ye2202105，8万。

4. 2023-2025同济大学附属杨浦医院院级重点学科，No. 2023YJXK01，10万。

5.《融合代谢组学与蛋白质组学策略：探索代谢相关脂肪性肝病病理过程中的代谢与蛋白调控网络及其分子机制》2024-2027，杨浦区卫健委面上项目，No. YPM202414，6万。

6.《基于ROS/NLRP3/Caspase-1通路探讨LXA4及其类似物BML-111在肾小球系膜细胞中的作用及分子机制》2024-2025，院基金（国自然培育项目），No. Se1202318，2万。

Advanced Science、Cancer Letters、International Journal of Biological Sciences、Journal of Translational Medicine、Journal of Leukocyte Biology、International Immunopharmacology、Therapeutic Advances in Medical Oncology、Cellular Signalling、Cancer Medicine、Experimental Cell Research、European Journal of Medical Research、Journal of Cosmetic Dermatology、Acta Histochemica、Renal Failure等杂志审稿专家，主持国家自然科学基金1项，省部级课题5项，市厅级课题4项，区级课题1项，院级课题4项。发表一作（含共一）及通讯作者SCI论文28篇（最高IF15.7）。

目前在研课题：

1.《穿刺洗脱液用于乳腺癌淋巴结或转移灶良恶性判断的研究方案》 2022-2024 上海市卫健委课题 No.202140232，20万。

2.《脂氧素 A4 调控肿瘤相关成纤维细胞 TGFβ-Smad2/3 通路抑制肝癌的机制研究》2021-2022 同济大学附属杨浦医院引进人才科研启动项目，10万。

3. 2022-2024同济大学附属杨浦医院第十批攀登计划项目，No. Ye2202105，8万。

4. 2023-2025同济大学附属杨浦医院院级重点学科，No. 2023YJXK01，10万。

5.《融合代谢组学与蛋白质组学策略：探索代谢相关脂肪性肝病病理过程中的代谢与蛋白调控网络及其分子机制》2024-2027，杨浦区卫健委面上项目，No. YPM202414，6万。

6.《基于ROS/NLRP3/Caspase-1通路探讨LXA4及其类似物BML-111在肾小球系膜细胞中的作用及分子机制》2024-2025，院基金（国自然培育项目），No. Se1202318，2万。

发表SCI论文：

1. Cheng J, Zheng J, Ma C, Li Y, Hao H^* (通讯作者). T-Cell Senescence: Unlocking the Tumor Immune “Dark Box” - A Multidimensional Analysis from Mechanism to Tumor Immunotherapeutic Intervention. Seminars in Cancer Biology, 2025, 113:190-209. (IF 15.7).

2. Miao S, Bai Y, Hao H^* (通讯作者). Case Report: A case of cervical burkitt lymphoma and literature review. Frontiers in Oncology, 2026, 15:1696219.

3. Zhou B, Zhao Q, Li X, Liu H, Hao H^* (通讯作者). Small intestinal NK/T-cell lymphoma with malignant peritoneal effusion as the first symptom: a case report and literature review. Frontiers in Medicine,2025, 12:1610820.

4. Yan L, Zhang J, Zheng J, Hao H^* (通讯作者). Biomarkers in spinal muscular atrophy. Frontiers in Neurology, 2025, 16:1636992.

5. Feng Y, Qu X, Hao H^* (通讯作者). Progress in the study of the effects of selective serotonin reuptake inhibitors (SSRIs) on the reproductive system. Frontiers in Pharmacology, 2025, 16:1567863.

6. Zhou B, Zheng J, Huang L, Hao H^* (通讯作者). Esophageal submucosal gland duct adenoma: a case report and literature review.  Frontiers in Oncology, 2025, 15:1525781.

7. Zheng J, Xu F, Li G, Lin M, Hao H^* (通讯作者).  The value of chromosome instability detected by low-pass whole-genome sequencing in preoperative prediction of sentinel lymphnode metastasis in breast cancer. Frontiers in Oncology, 2024, 14:1434526.

8. Zheng J, Hao H^* (通讯作者). Targeting Renal Damage: The ACE2/Ang-(1–7)/Mas Axis in Chronic Kidney Disease. Cellular Signalling, 2024,124:111413.

9. Zheng J, Hao H^* (通讯作者). The importance of cancer-associated fibroblasts in targeted therapies and drug resistance in breast cancer. Frontiers in Oncology, 2024, 13:1333839.

10. Zhou B, Guo M, Li X, Duan T, Peng L, Hao H^* (通讯作者).  Clinicopathological and molecular genetic alterations in monomorphic-epitheliotropic intestinal T-cell lymphoma of the small intestine. European Journal of Medical Research, 2024,29(1):191.

11. Zhou B, Gan X, Li X, Peng L, Hao H^* (通讯作者).  Ureter mixed neuroendocrine-non-neuroendocrine neoplasm: a case report and literature review. Frontiers in Oncology, 2024,14:1390350.

12. Wang Y, He Z, Hao H^* (通讯作者).  A case report of primary Kaposiform hemangioendothelioma of the humerus. International Journal of Immunopathology and Pharmacology, 2024:3946320241266914.

13. Yan L, Zheng J, Wang Q, Hao H^* (通讯作者).  Role of cancer-associated fibroblasts in colorectal cancer and their potential as therapeutic targets. Biochemical and Biophysical Research Communications, 2023, 681:127-135.

14. Zheng J, Tang C, Liu P, Hao H^* (通讯作者).  Carcinosarcoma of the ovary: a case report and literature review. Frontiers in Oncology, 2023,13:1278300.

15. Xu F, Zhou X, Lin L, Xu J, Feng Y, He Y, Hao H^* (通讯作者).  BML-111, the agonist of lipoxin A4, suppresses epithelial-mesenchymal transition and migration of MCF-7 cells via regulating the lipoxygenase pathway. International Journal of Immunopathology and Pharmacology, 2023,37:3946320231223826.

16. Hao H, Xie F, Xu F, Wang Q, Wu Y, Zhang D. LipoxinA4 analog BML-111 protects podocytes cultured in high-glucose medium against oxidative injury via activating Nrf2 pathway. International Immunopharmacology, 2022, 111:109170.

17. Zhang J, Zhou X, Hao H^* (通讯作者).  Macrophage phenotype-switching in cancer. EuropeanJournal of Pharmacology, 2022, 931:175229.

18. Xu F, Zhang J, Zhou X, Hao H^* (通讯作者).  Lipoxin A4 and its analog attenuate high fatdiet-induced atherosclerosis via Keap1/Nrf2 pathway. Experimental Cell Research, 2022, 412:113025.

19. Lin L, Wang Q, Xu F, Luo X, Xu J, Yan L,Li Q, Hao H^* (通讯作者).  BML-111, the lipoxin A4 agonist, modulates VEGF or CoCl2-inducedmigration, angiogenesis and permeability in tumor-derivedendothelial cells. Immunology Letters, 2021,230: 27-35.

20. Lin L, Luo XL, Wang L, Xu F, He YQ, Wang QY, Yuan CL,Xu J, Yan LP, Hao H^* (通讯作者).  BML-111 inhibits EMT, migration and metastasis of TAMs-stimulated triple-negative breast cancercells via ILK pathway. International Immunopharmacology, 2020, 85:106625.

21. Zhang T, Hao H (共同第一作者), Zhou ZQ, Zeng T, Zhang JM, Zhou XY. Lipoxin A4 inhibited the activation of Hepatic Stellate Cells -T6 cells by modulating profibrotic cytokines and NF-κB signaling pathway. Prostaglandins & Other Lipid Mediators, 2020,146:106380.

22. Zhang T, Hao H (共同第一作者), Zhou X. The Role of Lipoxin in Regulating Tumor Immune Microenvironments. Prostaglandins & Other Lipid Mediators, 2020,144:106341.

23. Li QF, Hao H (共同第一作者), Tu WS, Guo N, Zhou XY. Maresins: anti-inflammatory pro-resolving mediators with therapeutic potential. European Review for Medical and Pharmacological Sciences, 2020, 24: 7442-7453.

24. Chen QF, Hao H (共同第一作者), Kuang XD, Hu QD, Huang YH, Zhou XY. BML-111, a lipoxin receptoragonist, protects against acute injury via regulating the renin angiotensin-aldosterone system. Prostaglandins & Other Lipid Mediators, 2019,140:9-17.

25. Xu F, Zhou X, Hao J, Dai H, Zhang J, HeY, Hao H*（通讯作者). Lipoxin A4 and its analog suppress hepatocarcinoma cellepithelial-mesenchymal transition, migration and metastasis via regulatingintegrin-linked kinase axis. Prostaglandins & Other Lipid Mediators,2018,137:9-19.

26. Hao H*（通讯作者),  Xu F, Hao J, HeYQ, Zhou XY, Dai H, Wu LQ, Liu FR. Lipoxin A4 suppresses lipopolysaccharide-induced Hela cell proliferation, migration via NF-κB pathway. Inflammation, 2015,38(1):400-8.

27. Hao H, Liu M, Wu P, Cai L, Tang K, Yi P, Li Y, Chen Y, Ye D. Lipoxin A4 and its analog suppress hepatocellular carcinoma via remodeling tumor microenvironment. Cancer Letters, 2011,309(1):85-94.

28. Chen Y, Hao H（共同第一作者), He S, Cai L, Li Y, Hu S, Ye D, Hoidal J, Wu P, Chen X. Lipoxin A4 and its analogue suppress the tumor growth of transplanted H22 in mice: the role of antiangiogenesis. Molecular Cancer Therapeutics, 2010,9(8):2164-74.